A5090906445- Ovarian cancer diagnosis and treatment
- Sarcoma Diagnosis and Treatment
- PARP inhibition in cancer therapy
- Endometrial and Cervical Cancer Treatments
- Lymphoma Diagnosis and Treatment
- Cancer Immunotherapy and Biomarkers
- Gestational Trophoblastic Disease Studies
- Cancer Genomics and Diagnostics
- Uterine Myomas and Treatments
- Toxin Mechanisms and Immunotoxins
- Neuroendocrine Tumor Research Advances
- Prenatal Screening and Diagnostics
- IgG4-Related and Inflammatory Diseases
- Cancer survivorship and care
- Vascular Tumors and Angiosarcomas
- Bone Tumor Diagnosis and Treatments
- COVID-19 and healthcare impacts
- Gastric Cancer Management and Outcomes
- Gastrointestinal Tumor Research and Treatment
- Cancer Mechanisms and Therapy
- Neurofibromatosis and Schwannoma Cases
- Thyroid Cancer Diagnosis and Treatment
- Maternal and fetal healthcare
- COVID-19 Clinical Research Studies
- Lung Cancer Treatments and Mutations
Hospital Clínico San Carlos
2014-2025
Universidad Complutense de Madrid
2021-2025
University of Lausanne
2025
Instituto de Investigación Sanitaria del Hospital Clínico San Carlos
2020-2025
Spanish Ovarian Cancer Research Group
2024
European Organisation for Research and Treatment of Cancer
2024
Charles River Laboratories (Netherlands)
2021
John Wiley & Sons (United States)
2021
Hudson Institute
2021
Centro de Investigación Biomédica en Red de Cáncer
2020
Using patient reported-outcome measures (PROMs) in routine care has significant potential to benefit patients with cancer, but it is unclear how widely they are used practice. We conducted a cross-sectional survey (November 2023-April 2024) among healthcare professionals (HCPs) the European Organisation for Research and Treatment of Cancer (EORTC). Descriptive statistics chi-square tests assessed PROM use patterns, regional differences, barriers. Binary regression models compared barriers...
There is an unmet need for new therapies in metastatic ovarian cancer and basal-like breast since no curative are currently available. Immunotherapy has shown to be active several solid tumors, but particularly more those where a pre-activated immune state does exist. In this work, we aim identify biomarkers that could distinguish immune-activated tumors predict response cancer, as well their association with the level of tumor infiltration. We found combined expression IFNG, CD30, CXCL13,...
Abstract Gastrointestinal stromal tumor (GIST) is the most common malignant neoplasm of mesenchymal origin, and a paradigmatic model for successful rational development targeted therapies in cancer. The introduction tyrosine kinase inhibitors with activity against KIT/PDGFRA both localized advanced stages has remarkably improved survival disease formerly deemed resistant to all systemic therapies. These guidelines are elaborated by conjoint effort Spanish Society Medical Oncology (SEOM)...
Epithelioid Trophoblastic Tumor (ETT) and Placental Site (PSTT) are two of the rarest GTNs that share certain features at diagnosis management. Atypical Nodule (APSN) is a relatively new entity considered as premalignant lesion.
To evaluate atezolizumab combined with platinum-based chemotherapy (CT) followed by maintenance niraparib for late-relapsing recurrent ovarian cancer.
Abstract Background: Rucaparib is a poly(ADP-ribose) polymerase inhibitor approved in Europe as maintenance therapy for recurrent platinum-sensitive (Pt-S) ovarian cancer (OC). The Access Programme (RAP) was designed to provide early access rucaparib the above-mentioned indication, well patients with BRCA -mutated Pt-S or platinum-resistant (Pt-R) OC and no therapeutic alternatives. Methods: In this observational, retrospective study we analysed efficacy safety of within RAP Spain. Hospitals...
To evaluate outcomes of European cross-border multidisciplinary tumor boards in terms participation, adherence to treatment recommendations, and access novel strategies.The reference network for rare gynecological tumors (EURACAN G2 domain) aims improve the diagnosis, management, patients with these cancers. Cross-border were initiated facilitate intercollegiate clinical discussions across Europe increase patients' specialist recommendations trials. All healthcare providers invited...
We assessed trabectedin in patients with advanced uterine leiomyosarcoma (uLMS) real-life clinical practice given according to the marketing authorization.Thirty-six women from 11 tertiary hospitals across Spain who received after anthracycline-containing regimen/s were retrospectively analyzed. The primary endpoint was progression-free survival (PFS).Median PFS and overall (OS) since starting treatment 5.4 (95%CI: 3.5-7.3) 18.5 months 11.5-25.6), respectively. Median OS significantly higher...
Background and objectives: Social distancing quarantine implanted during the COVID-19 outbreak could have delayed accession of oncologic patients to hospitals treatments. This study analysed management sarcoma this period in five Spanish hospitals. Design methods: Clinical data from adult patients, soft tissue bone sarcomas, managed outbreak, 15 March 14 September 2020 (Covid cohort), were retrospectively collected time for diagnosis, surgery active treatments compared with same pre-pandemic...